206 related articles for article (PubMed ID: 27146196)
1. Carbon-13 and carbon-14 labeled dabigatran etexilate and tritium labeled dabigatran.
Latli B; Kiesling R; Aßfalg S; Chevliakov M; Hrapchak M; Campbell S; Gonnella N; Busacca CA; Senanayake CH
J Labelled Comp Radiopharm; 2016 Dec; 59(14):648-656. PubMed ID: 27146196
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
Blair HA; Keating GM
Drugs; 2017 Mar; 77(3):331-344. PubMed ID: 28185082
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Scott KA; Amirehsani KA
J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Ma TK; Yan BP; Lam YY
Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
8. The synthesis of a tritium, carbon-14, and stable isotope-labeled cathepsin C inhibitors.
Allen P; Bragg RA; Caffrey M; Ericsson C; Hickey MJ; Kingston LP; Elmore CS
J Labelled Comp Radiopharm; 2017 Feb; 60(2):124-129. PubMed ID: 27868229
[TBL] [Abstract][Full Text] [Related]
9. Syntheses of (3) H-labeled, (14) C-labeled, and (2) H4 -labeled SCH 444877, phosphodiesterase type 5 inhibitors.
Ren S; Hesk D; McNamara P; Koharski D; Hendershot S
J Labelled Comp Radiopharm; 2013; 56(9-10):480-4. PubMed ID: 24285525
[TBL] [Abstract][Full Text] [Related]
10. [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].
Meddahi S; Samama MM
J Mal Vasc; 2011 Feb; 36(1):24-32. PubMed ID: 21239127
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
12. Advances in oral anticoagulants: focus on dabigatran etexilate.
Hazlewood KA; Weiland CM
Expert Rev Clin Pharmacol; 2010 Nov; 3(6):727-37. PubMed ID: 22111776
[TBL] [Abstract][Full Text] [Related]
13. Preparation of tritium-labeled PF-622, a novel fatty acid amide hydrolase inhibitor.
Zhang Y
J Labelled Comp Radiopharm; 2017 Nov; 60(13):608-615. PubMed ID: 28869999
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
[TBL] [Abstract][Full Text] [Related]
15. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
16. Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
Lin R; Hoerr DC; Weaner LE; Salter R
J Labelled Comp Radiopharm; 2017 Nov; 60(13):616-623. PubMed ID: 28833358
[TBL] [Abstract][Full Text] [Related]
17. Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke.
von Wowern F; Brizzi M; Holst J
Eur J Case Rep Intern Med; 2017; 4(4):000569. PubMed ID: 30755937
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y
Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
Moore CH; Snashall J; Boniface K; Scott J
Am J Emerg Med; 2012 Nov; 30(9):2082.e1-2. PubMed ID: 22196949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
